Healthcare / BiotechnologyShanghai
$21.86
+0.38 (+1.77%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $125.0M · quality 63.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$9.1B
P/E
156.1x
↑EV/EBITDA
13.3x
↑ROE
1.4%
↑Gross Margin
79.4%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-8.5%
FCF CAGR
-2.1%
FCF margin
2.4%
FCF / Net income
0.25x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.39B · net income $131.8M · FCF $32.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.39B | $1.39B | $1.68B | $1.75B | $1.81B |
| Net Income | $131.8M | $131.8M | $342.8M | $465.9M | $714.0M |
| EBITDA | $349.6M | $349.6M | $576.8M | $703.1M | $960.6M |
| EPS | 0.32 | 0.32 | 0.83 | 1.12 | 1.71 |
| Gross Margin | 79.4% | 79.4% | 82.9% | 83.6% | 87.1% |
| Operating Margin | 14.2% | 14.2% | 27.1% | 33.9% | 42.9% |
| Net Margin | 9.5% | 9.5% | 20.5% | 26.6% | 39.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 28.42 | 28.42 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $32.8M | $32.8M | $138.5M | $125.0M | $34.9M |
| Returns | |||||
| ROE | 1.4% | 1.4% | 3.6% | 4.9% | 7.4% |
| Valuation | |||||
| P/E | 156.14 | 156.14 | 30.04 | 28.49 | 18.49 |
| EV/EBITDA | 13.30 | 13.30 | 10.08 | 12.44 | 7.73 |
| P/B | 0.96 | 0.96 | 1.08 | 1.38 | 1.37 |
| Growth & Yield | |||||
| Revenue Growth | -17.1% | -17.1% | -4.2% | -3.6% | — |
| EPS Growth | -61.4% | -61.4% | -25.9% | -34.5% | — |
| Dividend Yield | 0.5% | 0.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
82.3%
EPS terminal req.
$1.94
Spread vs growth
-143.8%
5Y implied EPS CAGR
49.0%
EPS terminal req.
$2.35
Spread vs growth
-110.4%
10Y implied EPS CAGR
28.0%
EPS terminal req.
$3.78
Spread vs growth
-89.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-14.2%
Start / end P/E
30.9x → 68.3x
EPS bridge
0.83 → 0.32
Residual
-74.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.